Ensysce Biosciences (ENSC) Preferred Stock Liabilities (2019 - 2020)
Ensysce Biosciences (ENSC) posted quarterly Preferred Stock Liabilities of $52935.0 for Q4 2020, down 99.97% year-over-year from $181.2 million in Q1 2020, and down 80.47% quarter-over-quarter from $270999.0 in Q3 2020.
Ensysce Biosciences (ENSC) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Preferred Stock Liabilities for 2 consecutive years, with $52935.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Preferred Stock Liabilities fell 99.97% year-over-year to $52935.0; the TTM figure through Dec 2020 stood at $52935.0 (down 99.97% YoY), while the FY2020 annual figure was $52935.0, down 99.97% from the prior year.
- Preferred Stock Liabilities slipped to $52935.0 in Q4 2020 per ENSC's latest filing, from $270999.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $181.2 million in Q4 2019 and bottomed at $52179.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 52,935.00 |
| Sep 30, 2020 | 270,999.00 |
| Jun 30, 2020 | 52,179.00 |
| Mar 31, 2020 | 4.54 Mn |
| Dec 31, 2019 | 181.17 Mn |